RIMI - Repository of the Institute for Medical Research
Institute for Medical Research
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   RIMI
  • Institut za medicinska istraživanja
  • Radovi istraživača / Researchers' publications
  • View Item
  •   RIMI
  • Institut za medicinska istraživanja
  • Radovi istraživača / Researchers' publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

The prognosis of CMV retinitis among patients with AIDS in Serbia

Authorized Users Only
2008
Authors
Dujić, A.
Jevtović, Đorđe
Salemović, Dubravka
Ranin, Jovan
Brmbolić, Branko
Đurković-Đaković, Olgica
Article (Published version)
Metadata
Show full item record
Abstract
Background: Cytomegalovirus (CMV) end-organ diseases, including CMV retinitis, are major opportunistic events in terminal AIDS patients. Methods: A retrospective study of 30 AIDS patients with CMV retinitis treated between 1997 and 2007 in Serbia was conducted to examine the prognosis and factors associated with survival. Results: Eighteen (60%) patients survived the mean follow-up period of 46.4 +/- 36 months. Patients' sex, mode of HIV transmission or previous AIDS diagnosis did not affect survival. Bilateral CMV retinitis predicted dissemination of CMV disease and poor prognosis (OR 7.8, 95% Cl 1.3-47.0, P = 0.012), but was not associated with blindness (P = 0.33). Among patients treated with HAART and CMV therapy the probability of surviving 10 years was 70%, while in those on CMV therapy alone, the median survival was 10 months (log rank P = 0.00). However, HAART itself was not sufficient to prevent blindness and the major predictor of blindness was a baseline CD4 cell count of le...ss than 50/mu L (OR 6.8, 95% Cl 1.1-41.8, P = 0.03). After CMV disease, most patients suffered other opportunistic events regardless of HAART introduction. Conclusion: Even in the HAART era patients with advanced immunodeficiency and CMV retinitis may not escape from the high risk mortality group, while survivors commonly lose sight.

Keywords:
AIDS / CMV retinitis / survival
Source:
Biomedicine & Pharmacotherapy, 2008, 62, 7, 443-447
Publisher:
  • Elsevier France-Editions Scientifiques Medicales Elsevier, Issy-Les-Moulineaux
Funding / projects:
  • Infekcije intercelularnim mikroorganizmima rastućeg značaja: transmisija, odnos patogen-domaćin, molekularna epidemiologija i klinički značaj (RS-145002)

DOI: 10.1016/j.biopha.2007.12.011

ISSN: 0753-3322

PubMed: 18243635

WoS: 000259357500031

Scopus: 2-s2.0-48349118363
[ Google Scholar ]
4
2
URI
http://rimi.imi.bg.ac.rs/handle/123456789/211
Collections
  • Radovi istraživača / Researchers' publications
Institution/Community
Institut za medicinska istraživanja
TY  - JOUR
AU  - Dujić, A.
AU  - Jevtović, Đorđe
AU  - Salemović, Dubravka
AU  - Ranin, Jovan
AU  - Brmbolić, Branko
AU  - Đurković-Đaković, Olgica
PY  - 2008
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/211
AB  - Background: Cytomegalovirus (CMV) end-organ diseases, including CMV retinitis, are major opportunistic events in terminal AIDS patients. Methods: A retrospective study of 30 AIDS patients with CMV retinitis treated between 1997 and 2007 in Serbia was conducted to examine the prognosis and factors associated with survival. Results: Eighteen (60%) patients survived the mean follow-up period of 46.4 +/- 36 months. Patients' sex, mode of HIV transmission or previous AIDS diagnosis did not affect survival. Bilateral CMV retinitis predicted dissemination of CMV disease and poor prognosis (OR 7.8, 95% Cl 1.3-47.0, P = 0.012), but was not associated with blindness (P = 0.33). Among patients treated with HAART and CMV therapy the probability of surviving 10 years was 70%, while in those on CMV therapy alone, the median survival was 10 months (log rank P = 0.00). However, HAART itself was not sufficient to prevent blindness and the major predictor of blindness was a baseline CD4 cell count of less than 50/mu L (OR 6.8, 95% Cl 1.1-41.8, P = 0.03). After CMV disease, most patients suffered other opportunistic events regardless of HAART introduction. Conclusion: Even in the HAART era patients with advanced immunodeficiency and CMV retinitis may not escape from the high risk mortality group, while survivors commonly lose sight.
PB  - Elsevier France-Editions Scientifiques Medicales Elsevier, Issy-Les-Moulineaux
T2  - Biomedicine & Pharmacotherapy
T1  - The prognosis of CMV retinitis among patients with AIDS in Serbia
EP  - 447
IS  - 7
SP  - 443
VL  - 62
DO  - 10.1016/j.biopha.2007.12.011
UR  - conv_2004
ER  - 
@article{
author = "Dujić, A. and Jevtović, Đorđe and Salemović, Dubravka and Ranin, Jovan and Brmbolić, Branko and Đurković-Đaković, Olgica",
year = "2008",
abstract = "Background: Cytomegalovirus (CMV) end-organ diseases, including CMV retinitis, are major opportunistic events in terminal AIDS patients. Methods: A retrospective study of 30 AIDS patients with CMV retinitis treated between 1997 and 2007 in Serbia was conducted to examine the prognosis and factors associated with survival. Results: Eighteen (60%) patients survived the mean follow-up period of 46.4 +/- 36 months. Patients' sex, mode of HIV transmission or previous AIDS diagnosis did not affect survival. Bilateral CMV retinitis predicted dissemination of CMV disease and poor prognosis (OR 7.8, 95% Cl 1.3-47.0, P = 0.012), but was not associated with blindness (P = 0.33). Among patients treated with HAART and CMV therapy the probability of surviving 10 years was 70%, while in those on CMV therapy alone, the median survival was 10 months (log rank P = 0.00). However, HAART itself was not sufficient to prevent blindness and the major predictor of blindness was a baseline CD4 cell count of less than 50/mu L (OR 6.8, 95% Cl 1.1-41.8, P = 0.03). After CMV disease, most patients suffered other opportunistic events regardless of HAART introduction. Conclusion: Even in the HAART era patients with advanced immunodeficiency and CMV retinitis may not escape from the high risk mortality group, while survivors commonly lose sight.",
publisher = "Elsevier France-Editions Scientifiques Medicales Elsevier, Issy-Les-Moulineaux",
journal = "Biomedicine & Pharmacotherapy",
title = "The prognosis of CMV retinitis among patients with AIDS in Serbia",
pages = "447-443",
number = "7",
volume = "62",
doi = "10.1016/j.biopha.2007.12.011",
url = "conv_2004"
}
Dujić, A., Jevtović, Đ., Salemović, D., Ranin, J., Brmbolić, B.,& Đurković-Đaković, O.. (2008). The prognosis of CMV retinitis among patients with AIDS in Serbia. in Biomedicine & Pharmacotherapy
Elsevier France-Editions Scientifiques Medicales Elsevier, Issy-Les-Moulineaux., 62(7), 443-447.
https://doi.org/10.1016/j.biopha.2007.12.011
conv_2004
Dujić A, Jevtović Đ, Salemović D, Ranin J, Brmbolić B, Đurković-Đaković O. The prognosis of CMV retinitis among patients with AIDS in Serbia. in Biomedicine & Pharmacotherapy. 2008;62(7):443-447.
doi:10.1016/j.biopha.2007.12.011
conv_2004 .
Dujić, A., Jevtović, Đorđe, Salemović, Dubravka, Ranin, Jovan, Brmbolić, Branko, Đurković-Đaković, Olgica, "The prognosis of CMV retinitis among patients with AIDS in Serbia" in Biomedicine & Pharmacotherapy, 62, no. 7 (2008):443-447,
https://doi.org/10.1016/j.biopha.2007.12.011 .,
conv_2004 .

DSpace software copyright © 2002-2015  DuraSpace
About RIMI | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About RIMI | Send Feedback

OpenAIRERCUB